Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

🇨🇳 Laotian Times (CN) —

AI Summary

Akeso, Inc. announced that its new antibody-drug conjugate AK157D1 has been cleared to start Phase I clinical trials for solid tumors by China's NMPA's Center for Drug Evaluation. This marks the third differentiated ADC in Akeso's oncology pipeline.

HONG KONG, Aug. 21, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients […]

Deals Health clinical trial antibody-drug conjugate solid tumors cancer treatment Akeso NMPA clearance

Read original source →